We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+34.63%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$208M
AUM Growth
-$246M
Cap. Flow
-$176M
Cap. Flow %
-84.46%
Top 10 Hldgs %
83.47%
Holding
151
New
27
Increased
12
Reduced
37
Closed
67

Top Buys

Rank Stock Value
1
HMTV
Hemisphere Media Group, Inc.
HMTV
+$9.46M
2
LOOP icon
Loop Industries
LOOP
+$2.38M
3
TRNX
Taronis Technologies, Inc. Common Stock
TRNX
+$1.52M
4
NVAX icon
Novavax
NVAX
+$1.36M
5
CODX
Co-Diagnostics
CODX
+$928K

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$37.5M
2
ESPR
Esperion Therapeutics
ESPR
+$6.39M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$4.97M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.47M
5
XERS icon
Xeris Biopharma Holdings
XERS
+$3.45M

Sector Composition

Rank Sector Weight
1 Healthcare 10.57%
2 Materials 0.95%
3 Consumer Discretionary 0.9%
4 Technology 0.61%
5 Industrials 0.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
126
Viking Therapeutics
VKTX
$3.93B
– –
-72,500
Closed -$607K
XBI icon
127
State Street SPDR S&P Biotech ETF
XBI
$10.1B
– –
-62,266
Closed -$4.47M
XERS icon
128
Xeris Biopharma Holdings
XERS
$1.42B
– –
-202,916
Closed -$3.45M
XNTK icon
129
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
– –
-694
Closed -$4.98M
TRAW icon
130
Traws Pharma
TRAW
$7.81M
– –
-127
Closed -$101K
GRCE
131
Grace Therapeutics
GRCE
$36.6M
– –
-5,729
Closed -$229K
VIRX
132
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-33
Closed -$47K
VIRX
133
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-11,433
Closed -$166K
SCPX
134
DELISTED
Scorpius Holdings, Inc.
SCPX
– –
-14
Closed -$384K
AVGR
135
DELISTED
Avinger, Inc. Common Stock
AVGR
– –
-37
Closed -$34K
MRNS
136
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-72
Closed -$82K
SOLOW
137
DELISTED
Electrameccanica Vehicles Corp. Ltd. Warrants
SOLOW
– –
-30,905
Closed -$14K
ISEE
138
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,438
Closed -$173K
ISEE
139
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,037,460
Closed -$2.44M
ISEE
140
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-133
Closed -$16K
BIOC
141
DELISTED
Biocept, Inc.
BIOC
– –
-192
Closed -$49K
CHEKZ
142
DELISTED
Check-Cap Ltd. Series C Warrant
CHEKZ
– –
-252,155
Closed -$101K
SRNE
143
DELISTED
Sorrento Therapeutics, Inc.
SRNE
– –
-84,536
Closed –
ZSAN
144
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-4,783
Closed -$355K
OTLKW
145
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
– –
-177,439
Closed -$27K
AVEO
146
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-1,073
Closed -$1.72M
FCSC
147
DELISTED
Fibrocell Science Inc.
FCSC
– –
-42,400
Closed -$64K
IPCI
148
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-1,944,978
Closed -$469K
RSLS
149
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
– –
-732,648
Closed -$187K
SGYPW
150
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
– –
-5,382
Closed -$59K
3 4 5
6
7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sabby Management held 151 positions worth $208M, down 54% from $455M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Sabby Management withdrew a net $176M in Q1 2019, closing 67 positions and reducing 37 holdings. Its most notable exit was Esperion Therapeutics, an estimated $6.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, down from 21% a quarter earlier, followed by Materials and Consumer Discretionary.

Against the trend, Sabby Management opened a new position in Hemisphere Media Group, Inc. worth $113K.

  • Sabby Management's largest Q1 2019 buy was Hemisphere Media Group, Inc.: 708,417 shares worth $113K.
  • Sabby Management added most to OpGen, Inc in Q1 2019, an estimated $921K increase.
  • Sabby Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $37.5M.
  • Sabby Management fully exited Esperion Therapeutics in Q1 2019, selling an estimated $6.39M.
  • Sabby Management's ten largest holdings make up 83% of its $208M portfolio in Q1 2019.
  • Sabby Management opened 27 new positions and closed 67 in Q1 2019.
  • Sabby Management's portfolio value fell 54% quarter-over-quarter to $208M.

Based on Sabby Management's 13F filing for Q1 2019, filed 15 May 2019.